You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

r/r B-ALL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Metabolically Armed CD19 CAR-T cells
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Feb 17, 2023

B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • single dose of CNCT19
  • (no location specified)
Dec 19, 2022

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • U-CAR-T Cells (LstCAR019)
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • UCAR-T Cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Human CD19 Targeted DASH CAR-T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

B-ALL Trial in Hangzhou (ThisCART19A)

Recruiting
  • B-ALL
  • ThisCART19A
  • Hangzhou, Zhejiang, China
  • +1 more
Apr 26, 2022

Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)

Recruiting
  • Acute Lymphoblastic Leukemia
  • cladribine, cytarabine,venetoclax
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 22, 2022

Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))

Not yet recruiting
  • Lymphoma Leukemia
  • allogeneic CAR19 regulatory T cells (CAR19-tTreg)
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Dec 6, 2022

Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That

Not yet recruiting
  • Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
  • Inotuzumab Ozogamicin
  • (no location specified)
Nov 3, 2022

Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19-CD22 Targeted T Cells Injection)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Human CD19-CD22 Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jan 24, 2022

Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in United States (PBCAR0191, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-Hodgkin Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • PBCAR0191
  • +2 more
  • Duarte, California
  • +9 more
Apr 18, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

CD19+ and CD 22+ B-ALL Trial in Langfang (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide,Fludarabine)

Recruiting
  • CD19+ and CD 22+ B-ALL
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 25, 2022

Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome Trial in Australia, Netherlands,

Recruiting
  • Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome
  • Duarte, California
  • +12 more
Jan 4, 2023

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

Acute Lymphoblastic Leukemia, in Relapse Trial in Bergamo, Monza (CARCIK-CD19)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • CARCIK-CD19
  • Bergamo, BG, Italy
  • +1 more
Feb 3, 2022

ACUTE LYMPHOBLASTIC LEUKEMIA Trial (Inotuzumab ozogamicin, ALLR3)

Not yet recruiting
  • ACUTE LYMPHOBLASTIC LEUKEMIA
  • (no location specified)
Feb 17, 2023

B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric Trial in Moscow (Chimeric Antigen Receptor T-Cell

Unknown status
  • B-cell Acute Lymphoblastic Leukemia
  • Acute Lymphocytic Leukemia, Pediatric
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Moscow, Russian Federation
    Dmitry Rogachev National Research Center of Pediatric Hematology
Apr 7, 2021

B-cell Acute Lymphoblastic Leukemia Trial in Tampa, Durham, Winston-Salem (Blinatumomab)

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • Tampa, Florida
  • +2 more
Feb 14, 2022

Acute Lymphocytic Leukemia Trial in Langfang (Autologous CD19-targeting CAR T cells)

Unknown status
  • Acute Lymphocytic Leukemia
  • Autologous CD19-targeting CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 18, 2021

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL) Trial in Tehran (CD19

Not yet recruiting
  • Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
  • Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
  • CD19 CAR engineered autologous T-cells
  • +3 more
  • Tehran, Iran, Islamic Republic of
  • +1 more
Mar 17, 2021

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023